Tango Therapeutics, Inc.
TNGX Real Time Price USDRecent trades of TNGX by members of U.S. Congress
No Congress Trading data for this ticker
Congress Trading Dashboard
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
---|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Recently reported changes by institutional investors
Quarterly net insider trading by TNGX's directors and management
Government lobbying spending instances
No Corporate Lobbying instances for this ticker
Corporate Lobbying DashboardEstimated quarterly lobbying spending
No Corporate Lobbying data for this ticker
Corporate Lobbying DashboardNew patents grants
-
Patent Title: Hdac inhibitors and therapeutic use thereof Jul. 23, 2024
-
Patent Title: Compounds and methods of use Jun. 04, 2024
-
Patent Title: Compounds and methods of use May. 21, 2024
-
Patent Title: Compounds and methods of use Nov. 08, 2022
-
Patent Title: Compounds and methods of use Aug. 03, 2021
Federal grants, loans, and purchases
No Government Contracts for this ticker
Government Contracts DashboardEstimated quarterly amount awarded from public contracts
Number of mentions of TNGX in WallStreetBets Daily Discussion
Recent insights relating to TNGX
Recent picks made for TNGX stock on CNBC
ETFs with the largest estimated holdings in TNGX
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view TNGX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.